BACKGROUND: Brief tools are needed to screen oncology outpatients for depressive symptoms. METHODS: Patients starting radiotherapy for the first diagnosis of any tumor completed distress screening tools, including the 9-item Patient Health Questionnaire (PHQ-9), the 2-item Patient Health Questionnaire (PHQ-2), the National Comprehensive Cancer Network Distress Thermometer (NCCN-DT), and the Hopkins Symptom Checklist (HSCL) (25-item version). Patients exceeding validated cutoff scores and a systematic sample of patients whose screening was negative completed the Structured Clinical Interview for DSM-IV (SCID) mood disorder modules via telephone. RESULTS: Four hundred sixty-three patients from 35 community-based radiation oncology sites and 2 academic radiation oncology sites were recruited. Sixty-six percent of the 455 eligible patients (n 5 299) were women, and the eligible patients had breast (45%), gastrointestinal (11%), lung (10%), gynecologic (6%), or other cancers (27%). Seventy-five (16.5%) exceeded screening cutoffs for depressive symptoms. Forty-two of these patients completed the SCID. Another 37 patients whose screening was negative completed the SCID. Among the 79 patients completing the SCID, 8 (10.1%) met the criteria for major depression, 2 (2.5%) met the criteria for dysthymia, and 6 (7.6%) met the criteria for an adjustment disorder. The PHQ-2 demonstrated good psychometric properties for screening for mood disorders with a cutoff score of 3 (receiver operating characteristic area under the curve [AUC], 0.83) and was comparable to the PHQ-9 ( > 9; AUC 5 0.85). The NCCN-DT did not detect depression (AUC 5 0.59).
INTRODUCTION
An Institute of Medicine report, Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs, reviews the nature and extent of unmet psychosocial needs among cancer survivors, including negative consequences for cancer treatment outcomes. 1 The Institute of Medicine report lists "identifying each patient's psychosocial health needs" as a requirement to ensure the provision of quality cancer care. Distress screening has increasingly been identified as an important component of quality cancer care. 2 The National Comprehensive Cancer Network (NCCN) distress management clinical practice guidelines were some of the first to recommend routine distress screening in oncology care settings. 3 The American Society of Clinical Oncology added psychosocial care, including distress screening, to the core set of quality indicators as part of the Quality Oncology Practice Initiative in 2008. 4 The American College of Surgeons Commission on Cancer now requires sites to implement distress screening programs to meet accreditation standards.
Distress is broadly defined by the NCCN as "a multifactorial unpleasant emotional experience of a psychological (cognitive, behavioral, emotional), social and/or spiritual nature that may interfere with the ability to cope with cancer, its physical symptoms and its treatment," including depression. 3 Estimates of the prevalence of depression among cancer patients vary considerably and depend on the methodology used to define depression and the sample characteristics (eg, active treatment, posttreatment surveillance, and palliative care). A recent meta-analysis estimated that 8% to 24% of cancer patients in nonpalliative care settings experience depression on the basis of pooled mean prevalence estimates. 7 Estimates of meta-analytical pooled prevalence based on studies that defined depression with psychiatric interviews were 25% in palliative care settings and 21% in oncology settings. 8 Although depression is less prevalent than anxiety among adults with cancer, 8, 9 the presence of depressive symptoms has been associated with poorer cancer outcomes. A meta-analysis of 25 independent studies found a 39% increase in mortality among cancer patients meeting diagnostic criteria for depression and a 25% increase in mortality risk among those with depressive symptoms after the researchers had controlled for prognostic variables. 10 The slope of depressive symptoms over time was predictive of survival among metastatic breast cancer patients. Women who reported decreased depression scores over a 12-month period had longer median survival than women with increased depression. 11 The association between depression and cancer outcomes underscores the importance of implementing effective strategies for the detection and management of cancer patients with symptoms of depression.
The primary objective of this trial was to assess the feasibility of a screening procedure for detecting mood disorders, including major depression, among cancer patients receiving definitive or palliative radiotherapy in community-based radiation oncology settings. The sensitivity and specificity of screening measures commonly used to detect mood disorders were evaluated. The secondary objectives of this study were to estimate the prevalence of mood disorders among cancer patients receiving definitive or palliative radiotherapy, to characterize the nature of the clinical services received to manage depression, and to determine patient preferences for and barriers to psychosocial care.
MATERIALS AND METHODS

Patients
Eligibility criteria included the following: the patient was 21 years old or older with his or her first diagnosis of any cancer type, the patient had stage I to IV cancer and was within 2 weeks of starting radiotherapy, the patient had telephone access, and the patient was fluent in English. Patients currently taking medication for depression or anxiety and those with a preexisting diagnosis of depression were eligible. Participants who had symptoms consistent with a psychotic disorder or were considered to potentially be at risk for suicide on the basis of staff clinical judgment were excluded from participating because of ethical considerations.
Procedures
This study was conducted through the National Cancer Institute-funded Radiation Therapy Oncology Group (RTOG) 0841 trial. With the exception of 2 academic sites (study investigators' institutions), participating sites were required to be designated by the National Cancer Institute as a community clinical oncology program. This study was approved by each participating site's institutional review board. Informed consent was obtained from all participants. Participating sites were required to complete a questionnaire describing the availability of psychosocial care at their site. This questionnaire was based on a survey conducted by Jacobsen and Ransom 12 to quantify the implementation of NCCN distress management guidelines at NCCN institutions.
As shown in Figure 1 , participants completed depression screening measures at the time of study enrollment. Staff at participating sites administered the screening and scored responses. Assessment results and participant information were provided to the RTOG coordinating center. Participants who exceeded clinical cutoff scores on screening measures completed an indepth assessment administered by telephone. A systematic sample of participants whose screening was negative also completed the telephone-based assessment. Participants meeting criteria for a mood disorder completed a 3-month telephone-based follow-up assessment.
Measures
Sociodemographic characteristics were obtained through patient questionnaires. Functional status and disease variables, including the cancer site, stage, and treatment, were extracted from participant medical records at the time of patient enrollment. Participants completed several patient-reported outcome measures to screen for depression, as described next.
Depression Screening Measures
Patient Health Questionnaire
The 9-item Patient Health Questionnaire (PHQ-9) is a 9-item scale composed of questions that correspond to
Original Article
Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (DSM-IV) diagnostic criteria for a major depressive episode. PHQ-9 scores range from 0 to 27; a higher score indicates greater depression. The PHQ-9 has been shown to be efficient and valid for both identifying depressed patients and sensitively measuring changes in symptoms over time. 13, 14 The 2 items that compose the 2-item Patient Health Questionnaire (PHQ-2) are contained within the PHQ-9. 15, 16 The PHQ-2 consists of the 2 main criteria for a major depressive episode, that is, depressed mood and anhedonia with a minimum duration of 2 weeks. PHQ-2 scores range from 0 to 6.
Hopkins Symptom Checklist (HSCL)
The 25-item version of the Hopkins Symptom Checklist (HSCL-25) 17 consists of a subset of items from the Symptom Checklist 90. 18 HSCL-25 scores range from 0 to 100; higher scores indicate elevated depression. The HSCL-25 is highly correlated with the 58-item version of the HSCL. 17 The HSCL-25 has been widely used to screen for depression among cancer patients 17 and has demonstrated excellent reliability (Cronbach's a > .90) and validity across a variety of general and medical populations.
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National Comprehensive Cancer Network Distress Thermometer (NCCN-DT)
The NCCN-DT consists of a single item with instructions to rate distress over the past week on a scale from 0 to 10, with higher scores indicating higher distress. The NCCN recommends using a score 4 as a cutoff for distress. The NCCN-DT has demonstrated good sensitivity and specificity for general distress. 3 Participants also completed a 15-item version of the Health Status Questionnaire. 20, 21 The results are not included in this report.
The SCID 22 was administered via telephone by trained, doctoral-level clinical psychologists. SCID modules for assessing a current major depressive episode, dysthymic disorder, bipolar disorder, and adjustment disorder were administered. Training and supervision for the SCID interviewers followed recommended procedures, 23 including reviewing the SCID user's guide, viewing SCID training videotapes, and rating a prerecorded interview administered by an expert interviewer. Study interviewers resolved questions related to SCID administration, scoring, and interpretation with the study chair. Administration of the SCID was required within 4 weeks of the completion of depression screening measures.
Participants also completed measures assessing current psychosocial care, preferences for psychosocial care, and barriers to receiving care.
Sample Size Calculations
The primary endpoint was the feasibility of implementing the screening procedure. It was hypothesized that the screening procedure would be demonstrated to be acceptable to patients and efficient at identifying patients with a mood disorder. The acceptability of the screening procedure was defined as the percentage of registered patients who successfully completed the depression screening measures (PHQ-9 and HSCL-25). The efficiency of the screening procedure was operationalized as 1) the percentage of patients whose screening was positive on the PHQ-9 or HSCL-25 and 2) the percentage of the positive-screen patients who met DSM-IV criteria for a current mood disorder according to the SCID interview. The screening procedure was defined as unacceptable if more than 25% of the patients failed to complete the PHQ-9 and the HSCL-25. Screening would be deemed inefficient if less than 34% of the patients exceeded clinical cutoffs on the PHQ-9 or the HSCL-25. On the basis of an estimated 15% attrition rate, screening would also be deemed inefficient if less than 33% of the patients whose screening was positive for depressive symptoms were diagnosed with a mood disorder. On the basis of the unacceptable (null hypothesis) and acceptable (alternative hypothesis) rates listed in Table 1, there would be 89% power to declare the screening tool successful at the .07 significance level. It was estimated that screening 400 patients would provide adequate power to evaluate the primary endpoint.
Statistical Methods
Descriptive statistics, such as frequencies, means, and medians, were used to display patient characteristics and screening and interview data. Specificity and sensitivity were assessed for each screening tool with the SCID interview to determine depression. Receiver operating characteristic curves (specifically the area under the curve [AUC]) were used to assess the accuracy of each measure in screening for depression, with an AUC of 0.5 indicating that the accuracy was similar to pure chance and an AUC of 1.0 indicating perfect accuracy.
Clinical Cutoff Scores for the Depression Screening Measures
An incomplete screen was defined as 1 or more unanswered items on the PHQ-9 or 3 or more unanswered items on the HSCL-25. A PHQ-9 score 10 or an HSCL-25 score 44 was categorized as a positive screening in accordance with established clinical cutoffs.
Managing Severe Distress and Suicidal Ideation
Detailed procedures for the management of patientreported severe distress or suicidal ideation were included in the protocol and were approved by local institutional review boards for participating sites. All sites were required to provide a document listing onsite and local psychosocial resources to RTOG headquarters before enrolling any patients; these were maintained on a password-protected Web site established for this study. This provided onsite staff and telephone interviewers with immediate access to referral information for distressed participants. If a participant reported a PHQ-9 score of 20 to 27 or a total HSCL-25 score of 65 to 100 during the depression screening, the site was required to document the clinical response and provide RTOG headquarters with this documentation. Participant-reported suicidal ideation on the PHQ-9 or HSCL-25 or during an SCID interview mandated an evaluation of risk by site staff or telephone interviewers along with documentation of the participant's risk and the clinical response, which was provided to RTOG headquarters. Telephone interviewers (SCID interviewers) obtained the participant's location at the beginning of the interview in the event that the participant reported risk of self-harm requiring the interviewer to notify local police. Telephone interviewers had access to the RTOG study-specific Web site to access local referral information as needed during study interviews.
RESULTS
Four hundred sixty-three patients were accrued from May 28, 2009 to March 11, 2011 from 37 sites, including 35 community clinical oncology program sites and 2 academic cancer centers. Eight of the 463 participants were ineligible (6 had ductal carcinoma in situ breast cancer, and 2 lacked verifying baseline information) and were not included in the analysis. Results are based on 455 participants. Patients' demographic and medical characteristics are presented in Table 2 .
Feasibility of Implementing the Screening Procedure
All eligible participants who enrolled (n 5 455) completed all depression screening measures, with no missing Table 3 .
SCID-Diagnosed Mood Disorders
A total of 79 SCID interviews were administered within 4 weeks of the administration of depression screening measures. SCID interviews were administered to a combined sample of participants who exceeded depression screening cutoffs (n 5 42) and a systematic sample of participants whose screening was negative (n 5 37), as shown in Table  4 . This represents 52.7% of the interviews required. Missing interviews were due to an inability to contact the patient (26%), the patient declining the interview (7%), a temporary regulatory hold (12%), and unknown reasons (3%). Among the 79 participants who completed the SCID, 42 were positively screened; 16 of these patients met the criteria for a mood disorder, and they represented 3.5% of the total study sample. A total of 2 participants (2.5%) met the criteria for dysthymia, 6 met the criteria for an adjustment disorder (7.6%), and 9 met the criteria for major depression (11.4%). One patient was diagnosed with both major depression and dysthymia. No patients were diagnosed with mania, hypomania, or a general medical condition or substance use causing mood-related symptoms. Figure 2 illustrates the sensitivity and specificity of the screening measures for detecting any mood disorder. The HSCL-25 had the highest sensitivity rate (0.88) but had a lower specificity rate (0.59). The NCCN-DT had the lowest specificity rate (0.52) but a higher sensitivity rate of 0.80. The PHQ-9 had sensitivity and specificity rates of 0.69 and 0.79, respectively, whereas the PHQ-2 had sensitivity and specificity rates of 0.63 and 0.86, respectively. As shown in this figure, the PHQ-9 (AUC 5 0.85) had good accuracy in classifying participants as true-positives or true-negatives. The PHQ-2 also maintained good accuracy (AUC 5 0.83) and was a much shorter tool than the PHQ-9. As shown in Figure 3 , a PHQ-2 cutoff of 3 or 4 maximized sensitivity and specificity. The HSCL-25 (AUC 5 0.80) had fair to good accuracy. The NCCN-DT (AUC 5 0.59) had poor accuracy in classifying patients with respect to the presence of mood disorders.
Psychosocial Care
Among the 36 respondents whose screening was positive on the PHQ-9 or HSCL and who completed the telephone assessment, 66.7% (n 5 24) reported current care for mood-related concerns. Oncologists and nurses were the most common providers (32%), and they were followed by mental health providers (17.9%) and primary care providers (15.4%). Counseling on site (89.8%) or off site (73.0%) and patient educational materials on managing depression (82.1%) were the most highly preferred psychosocial services. The most common barriers to psychosocial care included daily responsibilities (25.6%), physical symptoms (18.2%), the feeling that the distress severity did not warrant psychosocial care (18.0%), and difficulty with getting time off work (15.4%).
DISCUSSION
Screening for depression among adults receiving care in community-based radiation oncology settings is highly feasible, as evidenced by the depression screening measure completion rate. This finding was observed even in community-based radiotherapy settings that reportedly do not have distress screening procedures in place. In a large sample of participants, 16% exceeded clinical cutoff scores on standardized depression screening measures, and this is consistent with prior findings. 24 Upon further assessment, a much lower proportion of patients met DSM-IV criteria for mood disorders. The current results are consistent with the lower bound estimates of the prevalence of depression from a meta-analysis, which calculated approximate rates of depression of 5% to 16% for outpatients. 25 Studies that employed a similar methodology (ie, using expert interviewers to define depression) estimated a lower prevalence of depression and mood disorders. 25 Prevalence estimates from RTOG 0841 must be interpreted cautiously because this was not designed as an epidemiological study and the low participation rate (53%) in diagnostic interviews may have led to an underestimation of the prevalence of mood disorders.
One of the most compelling findings from this trial was the comparability of the PHQ-9 and the significantly shorter PHQ-2 in accurately categorizing participants with respect to the presence or absence of a current mood disorder. Both the PHQ-9 and the PHQ-2 have good accuracy in discriminating cancer patients with a mood disorder from those who do not meet DSM-IV criteria for a mood disorder, including major depression, dysthymia, and adjustment disorder. Findings suggest that the PHQ-2 can be used to screen for mood disorders without sacrificing the psychometric properties of the longer PHQ-9 and thus can Original Article minimize the patient and staff burden. No participants met the criteria for bipolar disorder. This finding is timely because of the recent trend of incorporating psychosocial care as a core cancer care quality indicator and the American College of Surgeons Commission on Cancer distress screening accreditation requirement. 5, 6 The longer 25-item HSCL did not offer any additional precision in accurately classifying participants with respect to the presence or absence of a mood disorder. In contrast, the NCCN-DT had poor accuracy for detecting mood disorders. Using the NCCN-DT to detect mood disorders is akin to using a thermometer to quantify a patient's body weight; the NCCN-DT simply does not accurately measure mood disorders, including depression. Previous research has established that the NCCN-DT can adequately detect clinically significant anxiety 26 ; however, research has shown that depression, not anxiety, is associated with poorer significant outcomes such as survival. Sites using the NCCN-DT to screen for distress should also administer the PHQ-2 to be sure to capture clinically significant mood disturbances.
The majority of the patients whose screening was positive for mood-related symptoms (70%) reported current care for mood-related concerns. The flip side of this finding is that 30% of the participants with elevated symptoms were not receiving care. This finding supports the need to implement systematic distress screening with in-depth assessments and/or referrals for participants whose screening is positive. Cancer center-based oncology providers were identified as the most common sources of psychosocial care, and they were followed by mental health and primary care providers. This is consistent with a strong preference for onsite counseling as the most preferred mode of psychosocial care delivery. The most common patient-related barriers to receiving psychosocial care (daily responsibilities and physical symptom burden) can be addressed through psychosocial care at the point of cancer care delivery and through nontraditional strategies for psychosocial care delivery such as eHealth and mHealth approaches. 27 The limitations of this study include the low SCID completion rate among participants whose screening was positive. Missing interviews due to an inability to contact participants may have introduced a bias if the participants with more severe distress were more difficult to reach. An additional limitation is the disproportionate representation of breast cancer patients and women in this sample; this potentially limits generalizability.
In summary, the PHQ-2 is a feasible approach for screening for mood-related symptoms among cancer patients receiving treatment in community-based radiation oncology practices. Because of the widespread use of radiotherapy to treat cancer, the brief and accurate detection of patients experiencing mood disorders in radiation oncology settings can lead to the improved detection and management of distress. The PHQ-2 is an effective tool for identifying cancer patients with mood disorders, is comparable to the longer PHQ-9, and is superior to the widely used NCCN-DT.
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